 Angiotensin-( 
Introduction
The octapeptide angiotensin II (Ang II) is the main active component of the renin-angiotensin-aldosterone system (RAAS), that plays an important role in blood pressure regulation, producing vasoconstriction, salt and water reabsorption, and contributes to the development of hypertension. 1 Most of the physiological actions of this peptide are mediated by the angiotensin type 1 (AT 1 )receptor. 2 Consequently, drugs blocking the AT 1receptor constitute an alternative way of blocking the RAAS and have been developed as a new class of antihypertensive agents.
Recently, it was shown in a small study (ELITE I) that treatment with losartan, the first nonpeptide, selective and competitive AT 1 -receptor antag-onist, 3 apart from lowering blood pressure, may reduce mortality in patients with heart failure although this has not been confirmed in larger studies (ELITE II). 4, 5 The mechanism underlining this phenomenon is not entirely understood.
It has been postulated that the actions of losartan are not solely attributable to AT 1 -receptor blockade, but could also depend on the excessive formation and action of angiotensin II (Ang II)derived peptides, mainly angiotensin-(1-7) [Ang- (1) (2) (3) (4) (5) (6) (7) ]. 6 This paracrine heptapeptide is synthesised directly from Ang II, acts as a vasodilator hormone, limiting both the pressor and proliferative actions of Ang II, and is known as a potent stimulator of nitric oxide (NO) and prostacyclin (PGI 2 ) release. 7 To date, a study from our group has demonstrated the antithrombotic effect of losartan in an experimental thrombosis model. 8 We have shown that the antithrombotic action of losartan depends mainly on NO release. 9 One possibility is that Ang-(1-7), by counterbalancing the effects of Ang II, is responsible for some of the pharmacological effects of losartan.Therefore, in the present study we compared the antithrombotic actions of losartan and Ang-(1-7).
Materials and methods

Animals and renovascular hypertension induction
Spontaneously hypertensive rats (SHR) (290-320 g) and male Wistar rats (160-180 g) were used in this study. The animals were housed in a room with a 12-hour light/dark cycle, in group cages as appropriate, were given tap water and fed a standard rat chow. 24 hours prior to induction of venous thrombosis, the rats were deprived of food, but had free access to water.
A two-kidney, one-clip model of hypertension (2K-1C) was induced by partial, standardised clipping of the left renal artery under pentobarbital anaesthesia (40mg/kg, i.p.). The induction of hypertension lasted six weeks. 9 Procedures involving the animals and their care conformed with the institutional guidelines, in compliance with national and international laws and Guidelines for the Use of Animals in Biomedical Research (Thromb Haemost 1987; 58:1078-84).
Experimental protocol
SHR rats received losartan either as a single dose (acute dosing, 10 mg/kg; p.o.) or chronically (chronic dosing, 10 mg/kg p.o. daily) for three weeks. 2K-1C rats were treated with a single dose of losartan (10 mg/kg; p.o.). The increase in the level of Ang-(1-7) in 2K-1C rats was achieved by a continuous two-hour infusion (1, 10, 100 pmol/ kg/min, i.v.) (infusion pump Ascor, Poland). Control animals in the losartan set of experiments (CON-L) received distilled water (0.5 ml, p.o.) whilst controls in the Ang-(1-7) set of experiments (CON-A) received isotomic saline (2 ml/kg/h, i.v.).
Blood pressure measurement
Systolic blood pressure (SBP) was measured by the 'tail cuff' method (Student Oscillograph, Harvard Rat Tail Blood Pressure Monitor) 10 before starting the administration of drugs and two hours after losartan administration in acute dosing experiments or five minutes before venous thrombosis induction in chronic dosing experiments. Each value was the average of three consecutive readings.
Blood pressure in rats receiving Ang-(1-7) infusion was measured directly through a cannula filled with heparin solution (150 U/ml), placed in the right common carotid artery and connected to a pressure transducer (Gould P231D) and a monitor Trendoscope 8031 (SandW Vickers Ltd, Bialystok, Poland).
Venous thrombosis model
Venous thrombosis was performed as previously described by Reyers et al. 11 two hours after losartan administration in acute experiments, at the end of the dosing period in chronic treatment experiments, or 10 minutes after the start of the Ang-(1-7) infusion.The animals were anaesthetised with pentobarbital (40 mg/kg, i.p.). Briefly, the abdomen was opened, the vena cava was carefully separated from the surrounding tissues and then ligated tightly with a cotton thread just below the left renal vein. Subsequently, the abdomen was closed with a double layer of sutures (peritoneum with muscles and the skin separately). After two hours the animals were re-anaesthetised and the abdomen was then reopened, the vena cava was carefully dissected and inspected for the presence of thrombus.The thrombus was kept at 37°C and after 24 hours its dry weight was measured.
Platelet adhesion to fibrillar collagen
Platelet adhesion was carried out as described previously. 12 In ex vivo experiments, blood was taken from the heart of 2K1C rats, two hours after a single dose of losartan. The experiments with Ang-(1-7) were performed in in vitro conditions. Blood samples were obtained from the hearts of 2K-1C rats not receiving saline infusion. Ang-(1-7) was added in concentrations of 10 -6 and 10 -5 M. Platelet samples (1.5x10 8 platelets in 0.25 ml) were incubated in an Elvi aggregometer at 37°C and stirred at 900 r.p.m. with EDTA (5mM) to prevent platelet aggregation. Collagen (50µg ml -1 ) was added after five minutes (losartan experiments) or 30 minutes [Ang-(1-7) experiments], and the samples were incubated for a further 10 minutes. Platelets were counted before and 15 minutes after addition of collagen, using a light microscope; the difference in platelet count was taken as an index of their adhesion to collagen. The control group in the losartan set of experiments received distilled water (CON-L). In the control group in the Ang-(1-7) in vitro experiments isotonic saline (CON-A) was added instead of Ang-(1-7) as control.
Haemostatic parameters
Blood samples were taken from the heart two hours after venous thrombosis induction. Prothrombin time (PT), activated partial thromboplastin time (APTT) and euglobulin clot lysis time (ECLT) were determined by routine laboratory assays.
Chemicals and drugs
Losartan (DuP 753, kindly provided by DuPont Merck Pharmaceutical Co., USA),Ang-(1-7) (Sigma Chemical Co., USA), collagen (Chronolog, USA), 3.13% trisodium citrate (Polish Chemical Reagents, Gliwice, Poland), heparin (Heparinum, Polfa, Poland), pentobarbital (Vetbutal, Polfa, Poland) were used in the experiments.
Statistical analyses
The data are shown as mean ± SEM. Multiple group comparisons were performed by one-way analysis of variance (ANOVA) followed by a Student-Neuman-Keuls test; p values of less than 0.05 were considered significant.
Results
Venous thrombosis
In SHR, single dosing as well as chronic treatment with losartan induced a marked decrease in thrombus weight (1.6±0.6 mg and 1.2±0.3 mg, respectively vs. control 2.9±0.8 mg; p<0.05, p<0.05) ( Figure 1 ).A single dose of losartan in 2K-1C rats also reduced this parameter (1.39±0.29 mg vs. control 3.25±0.62 mg; p<0.01). Infusion of Ang-(1-7) to 2K-1C rats also significantly reduced the thrombus weight (1.01±0.34 mg, 1.23±0.38 mg and 2.17±0.36 mg for 1, 10, 100 pmol/kg/min, respectively vs. control 3.58±0.6 mg; p<0.01, p<0.01, p<0.05) ( Figure 2 ). However, Ang-(1-7) 
Blood pressure
Single doses and chronic dosing with losartan to SHR produced a significant decrease in SBP (161±10 mmHg and 144±6 mmHg, respectively vs. control 204±7 mmHg; p<0.001, p<0.001). In 2K-1C rats, acute dosing of losartan also reduced SBP (160±4 mmHg vs. control 137±4 mmHg; p<0.001).
None of the three doses of exogenous Ang-(1-7) infusion influenced SBP (data not shown).
Platelet adhesion to fibrillar collagen
Single doses of losartan to 2K-1C significantly reduced platelet adhesion to fibrillar collagen (24.9±1.0% vs. 31.5±1.1%; p<0.001). The incubation of 2K-1C platelets samples with Ang-(1-7) also reduced adhesion to fibrillar collagen (38.4±0.1% and 33.8±0.8% for 10 -6 and 10 -5 M, respectively vs. control 40.0±0.6%; p<0.05, p<0.001) ( Figure 3 ).
Haemostatic parameters
There were no apparent changes in PT,APTT and ECLT in SHR receiving either single or multiple doses of losartan, or in 2K-1C rats receiving acute losartan dosing or Ang-(1-7) infusion. (Table 1) .
Discussion
In the present study, we have demonstrated that losartan exerts an antithrombotic effect which can be mimicked by the continuous infusion of Ang-(1-7). At the same time, losartan treatment reduced platelet adhesion to fibrillar collagen, as did the incubation of platelet preparations with increasing doses of Ang-(1-7). To our knowledge, these are the first data indicating an involvement of Ang-(1-7) in thrombotic processes.
In the first step of our study, we demonstrated the antithrombotic effect of both acute and chronic treatment with losartan in SHR. Thus, we con-firmed and extended our previous results pointing to the role of angiotensin-converting enzyme (ACE) inhibitors and AT 1 -receptor antagonists in venous thrombosis using the same experimental model. 9, 13 However, the mechanism of pathogenesis of hypertension in SHR is not fully elucidated and it is well known that these animals suffer from many anatomical and biochemical peculiarities. 14 Therefore, to exclude the possibility that the observed antithrombotic effect may be specific only for SHR, we performed additional experiments using a renal hypertension model (2K-1C), which is better characterised and is known to be RAAS-dependent. 15 We demonstrated that acute losartan administration reduced the thrombus weight in 2K-1C rats and SHR to a similar extent. Thus, in the next steps of our study we used the 2K-1C experimental model.
Recently, it has been suggested that Ang-(1-7), concentrations of which increase during treatment with AT 1 -receptor antagonists, may be responsible for some of the beneficial effects of losartan. 16 Since it has been shown that Ang-(1-7) liberates NO and PGI 2 , 7 both strong antithrombotic endothelial mediators, it can be speculated that the observed effect of losartan may depend on Ang-(1-7) formation. We explored this possibility by examining the effect of a continuous infusion of increasing doses of Ang-(1-7) on venous thrombosis.We have shown a striking similarity between the antithrombotic effect of losartan and that of Ang-(1-7). Unexpectedly, in the case of Ang-(1-7) we obtained an inverse dose-response curve of thrombus weight reduction. This may be due to the presence of an Ang-(1-7) metabolite, angiotensin-(3-7) [Ang- (3) (4) (5) (6) (7) ]. Ang-(3-7) has been found to be an agonist at the angiotensin type 4 (AT 4 ) receptor site 17 which is responsible for the release of plasminogen activator inhibitor type 1 (PAI-1) leading to a decrease in fibrinolytic activity, 18 and thus promoting thrombosis.
Since platelet adhesion to subendothelial matrix is an important step in thrombus development and since NO is known as the mediator that may reduce platelet adhesion, 19 we decided to study the role of platelets in our experimental model. Of the four angiotensin receptors, the AT 1receptor was the only type demonstrated to play a role in human platelet activation. 20, 21 Therefore, we hypothesised that blockade of this receptor may reduce platelet adhesion to fibrillar collagen. Indeed, in the next step of our study we demonstrated the decreased adhesion of thrombocytes to collagen following treatment with losartan. A similar effect was obtained after incubation of platelets with Ang-(1-7). However, unlike our in vivo experiments, the antiadhesive effect of the peptide increased with higher doses. One possible explanation for this discrepancy may be the lack of AT 4 -receptors on the platelet surface: there is no experimental evidence for the presence of this binding site in thrombocytes.Thus, the AT 4 -receptor-dependent component of PAI-1 release may be lacking in platelets, but not in endothelium which may result in different dose-response relationships in our in vivo and in vitro experiments.
In the present study we used relatively high concentrations of Ang- (1-7) . The question therefore remains whether the observed antithrombotic effect of this peptide is physiologically relevant. The treatment of hypertensive rats with losartan results in an increase in Ang-(1-7) plasma levels from 5-10 to 15-40 fmol/ml, depending on the experimental model. 16, 22 Although, we did not measure the concentration of Ang-(1-7) following infusions it can be roughly calculated that the final concentration of the peptide in our experiments amounted to approximately 20 fmol/ml which closely resembles the conditions observed after losartan treatment. One might also argue that the concentration of Ang-(1-7) required to inhibit platelet adhesion in vitro is very high. However, thrombosis should be considered as a multifactoral event in which other cells such us neutrophils, endothelial cells and other active substances are engaged. Overall platelet reactivity depends on the interaction that occurs between these factors. Only the direct effect of Ang-(1-7) on platelet adhesion was analysed in the present study.
In our study, neither losartan nor Ang-(1-7) significantly modified prothrombin time, activated partial thromboplastin time and euglobulin clot lysis time. Thus, changes in coagulation and fibri-nolysis pathways do not appear to be responsible for the effects observed in the present study.
One may suggest that the antithrombotic activity of losartan and Ang-(1-7) may result from blood pressure reduction. However, we have previously demonstrated that the antithrombotic activity of captopril, an ACE inhibitor, did not correlate with blood pressure reduction. 13 In this study, losartan administration reduced SBP but two-hour infusion of Ang-(1-7) had no such effect.Therefore, the contribution of the hypotensive component in the antithrombotic effect should be excluded.
In summary, we have demonstrated that both losartan and Ang-(1-7) reduce thrombus weight in a venous thrombosis model and decrease the adhesion of platelets to fibrillar collagen.Although this parallelism is striking and suggests a role of Ang-(1-7) in the antithrombotic effect of losartan, some other mechanisms must be taken into consideration. Since, there is a general agreement that losartan blocks TXA2/PGH2 receptors on platelets, 23-25 the involvement of the arachidonic acid cascade in the antithrombotic effect of losartan cannot be excluded and needs to be elucidated in our experimental model. Nevertheless, to our knowledge there is no data indicating an involvement of TXA2/PGH2 receptor in the effect of Ang-(1-7). Table 1 Effect of single dose and chronic treatment with losartan (10 mg/kg, p.o.; LOS acute, LOS chronic) in SHR, single dose of losartan (10 mg/kg, p.o; LOS acute) in 2K-1C rats or Ang-(1-7) infusion (1,10, 100 pmol/kg/min) to 2K-1C rats on haemostatic parameters (PT = prothrombin time, APTT = activated partial thromboplastin time, ECLT = euglobulin clot lysis time); CON-L = losartan control groups; CON-A = Ang-(1-7) control group.Values are expressed as mean ± SEM of 10-15 rats. 
